Zacks: Brokerages Anticipate Zynex, Inc. (NASDAQ:ZYXI) Will Announce Earnings of $0.05 Per Share

Equities analysts expect that Zynex, Inc. (NASDAQ:ZYXI – Get Rating) will announce earnings per share of $0.05 for the current quarter, Zacks reports. Three analysts have issued estimates for Zynex’s earnings. The highest EPS estimate is $0.06 and the lowest is $0.04. Zynex reported earnings of ($0.02) per share in the same quarter last year, which would indicate a positive year over year growth rate of 350%. The firm is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Zynex will report full year earnings of $0.50 per share for the current year, with EPS estimates ranging from $0.43 to $0.54. For the next year, analysts forecast that the business will report earnings of $0.72 per share, with EPS estimates ranging from $0.55 to $0.89. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Zynex.

Zynex (NASDAQ:ZYXI – Get Rating) last issued its earnings results on Thursday, February 24th. The company reported $0.23 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.04. Zynex had a return on equity of 27.28% and a net margin of 13.13%. The company had revenue of $40.37 million during the quarter, compared to the consensus estimate of $41.06 million.

ZYXI has been the subject of several analyst reports. TheStreet downgraded Zynex from a “b-” rating to a “c+” rating in a research report on Monday, December 20th. HC Wainwright decreased their target price on Zynex from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, February 25th. Piper Sandler decreased their target price on Zynex from $13.00 to $7.00 in a research report on Friday, February 25th. Zacks Investment Research downgraded Zynex from a “hold” rating to a “sell” rating in a report on Friday, February 25th. Finally, B. Riley reduced their price target on Zynex from $15.50 to $10.00 and set a “buy” rating for the company in a report on Monday, February 28th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $14.70.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Metropolitan Life Insurance Co NY acquired a new stake in Zynex during the third quarter valued at approximately $65,000. Denali Advisors LLC acquired a new stake in Zynex during the fourth quarter valued at approximately $70,000. Nisa Investment Advisors LLC acquired a new stake in Zynex during the fourth quarter valued at approximately $63,000. Keebeck Alpha LP acquired a new stake in Zynex during the third quarter valued at approximately $127,000. Finally, OLD Mission Capital LLC acquired a new stake in Zynex during the third quarter valued at approximately $211,000. Hedge funds and other institutional investors own 27.23% of the company’s stock.

Shares of NASDAQ ZYXI opened at $6.85 on Wednesday. Zynex has a 1-year low of $4.97 and a 1-year high of $16.26. The business has a 50-day moving average of $6.31 and a 200-day moving average of $9.50. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.62 and a quick ratio of 3.15. The company has a market capitalization of $272.52 million, a price-to-earnings ratio of 15.60 and a beta of 0.90.

About Zynex (Get Rating)

Zynex, Inc, through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device.

Featured Articles